Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05509023 · ClinicalTrials.gov registry record · Phase 2
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
A Phase 2 study of Atopic Dermatitis, sponsored by Q32 Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
- 20
- Study locations
NCT05509023: Active Phase 2 study of Atopic Dermatitis, sponsored by Q32 Bio.
NCT05509023 is a Phase 2 study of Atopic Dermatitis that is active but no longer recruiting, run by Q32 Bio. The registered enrollment target is 102 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05509023, a Phase 2 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Q32 Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ADX-914
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- California Allergy and Asthma Medical Group- Los Angeles - Los Angeles
- Integrative Skin Science and Research - Sacramento
- Dermatology Institute and Skin Care Center - Santa Monica
- Torrance Clinical Research Institute Inc. - Torrance
- Integrated Research of Inland, Inc. - Upland
Florida
- RM Medical Research Inc. - Homestead
- Medical Research Center of Miami - Miami
- Well Pharma Medical Research Corporation - Miami
- GCP Research - St. Petersburg
Alabama
- Cahaba Dermatology Skin Health Center - Birmingham
Georgia
- Advanced Medical Research, PC - Sandy Springs
Idaho
- Treasure Valley Medical Research - Boise
Illinois
- Sneeze wheeze and Itch Associates LLC - Normal
Indiana
- Southern Indiana Clinical Trials - New Albany
Maryland
- Visage Clinical Research - Largo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What the registry record for NCT05509023 still lists
NCT05509023 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05509023 names 20 study sites across 12 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05509023 about?
NCT05509023 is a clinical study titled "Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)". This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
What is the current status of trial NCT05509023?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2022-09-30. Estimated completion is 2024-12.
What conditions does trial NCT05509023 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05509023?
The interventions under investigation include: Placebo (DRUG), ADX-914 (DRUG).
Who is sponsoring clinical trial NCT05509023?
This trial is sponsored by Q32 Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05509023 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05509023's enrollment target sits among peer trials
102 84th of 150 higher than 67 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI